[Phase I study of SM-5887, a new anthracycline derivative].
SM-5887, a new totally synthetic anthracycline derivative, was studied in a phase I setting. Twenty-nine evaluable courses of treatment were conducted in groups at doses increasing from 10 to 130 mg/m2. At 130 mg/m2 the median lowest WBC count was 0.7 x 10(3)/mm3 (range 0.3-1.8) and the median lowest platelet count was 57 x 10(3)/mm3 (range 4-176). Nonhematological side effects were mild gastrointestinal symptoms and hair loss. The recommended dose and schedule for a phase II setting is 100 mg/m2 every 3 weeks.
Inoue
K
K
Dept. of Clinical Oncology, Cancer Institute Hospital, Tokyo, Japan.
Ogawa
M
M
Horikoshi
N
N
Mukaiyama
T
T
Itoh
Y
Y
Imajoh
K
K
Ozeki
H
H
Nagamine
D
D
Shinagawa
K
K
D000328:Adult; D000368:Aged; D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C055866:amrubicin